valsartan has been researched along with Apoplexy in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (41.67) | 29.6817 |
| 2010's | 22 (45.83) | 24.3611 |
| 2020's | 6 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, J; Wang, CQ; Wang, Y; Zhang, JF | 1 |
| Abraham, WT; Butt, JH; Desai, AS; Dewan, P; Dickstein, K; Ferreira, JP; Jhund, PS; Køber, L; McMurray, JJV; Packer, M; Petrie, MC; Rouleau, JL; Solomon, SD; Stewart, S; Swedberg, K; Zile, MR | 1 |
| Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R | 1 |
| Lee, YB; Shin, DH; Song, S | 1 |
| McAlister, FA; Youngson, E | 1 |
| Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB | 1 |
| Letizia, C; Petramala, L | 1 |
| Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA | 1 |
| Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Park, RW; Yoon, D | 1 |
| Bianchi, F; Cotugno, M; Forte, M; Madonna, M; Marchitti, S; Rubattu, S; Stanzione, R; Volpe, M | 1 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Bae, HJ; Hong, KS; Kang, DW; Koo, J; Lee, BC; Lee, J; Oh, MS; Park, JM; Yu, KH | 1 |
| Gröhn, O; Haapalinna, A; Haasio, K; Hyttilä-Hopponen, M; Kivikko, M; Kuoppamäki, M; Levijoki, J; Miettinen, R; Pollesello, P; Puoliväli, J; Sallinen, J; Tähtivaara, L; Yrjänheikki, J | 1 |
| Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N | 1 |
| Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D | 1 |
| Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E | 1 |
| Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Hall, AS; Strauss, MH | 1 |
| Eto, T; Imai, Y; Imaizumi, T; Ito, S; Kikuchi, K; Kimura, G; Matsuoka, H; Ogihara, T; Rakugi, H; Saruta, T; Shimada, K; Shimamoto, K; Takishita, S; Ueshima, H | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Koide, M; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T | 1 |
| Williams, B | 1 |
| Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Ebrahimian, T; Gratton, JP; He, Y; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Victor, RG | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Achard, JM; Boutitie, F; Fournier, A; Gueyffier, F; Temmar, M | 1 |
| Rupp, H | 1 |
| Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL | 1 |
| Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L | 1 |
6 review(s) available for valsartan and Apoplexy
| Article | Year |
|---|---|
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
VALUE and supremacy of blood pressure control for cardiovascular protection.
Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan | 2007 |
14 trial(s) available for valsartan and Apoplexy
| Article | Year |
|---|---|
Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Double-Blind Method; Humans; Prospective Studies; Pyrimidines; Republic of Korea; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2019 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan | 2020 |
Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cerebrovascular Circulation; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Stroke; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open-label, blinded-end-point trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Sequence Data; Nervous System Diseases; Outcome Assessment, Health Care; Prospective Studies; Stroke; Valsartan | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Systole; Treatment Outcome; Valsartan | 2016 |
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Male; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome; Valsartan | 2016 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Medical History Taking; Patient Selection; Proportional Hazards Models; Reference Values; Stroke; Systole; Tetrazoles; Valine; Valsartan | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Prospective Studies; Risk Factors; Stroke; Survival Rate; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
29 other study(ies) available for valsartan and Apoplexy
| Article | Year |
|---|---|
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Brain Ischemia; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stroke; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atmosphere; Biphenyl Compounds; Comorbidity; Drug Combinations; Heart Failure; Humans; Hypertension; Multimorbidity; Stroke; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan | 2023 |
Impact of the Generic Valsartan Recall in Alberta, Canada.
Topics: Aged; Alberta; Antihypertensive Agents; Carcinogens; Databases, Factual; Dimethylnitrosamine; Drug Recalls; Drug Substitution; Drugs, Generic; Emergency Service, Hospital; Humans; Hypertension; Office Visits; Stroke; Valsartan | 2020 |
Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cardiology; Drug Combinations; Humans; Neprilysin; Stroke; Tetrazoles; Valsartan | 2020 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stroke; Valsartan | 2018 |
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Drug Combinations; Hypertension; Male; Neprilysin; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valsartan | 2018 |
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Clinical trial rigging: again!
Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Retraction of Publication as Topic; Scientific Misconduct; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Blood Volume; Brain; Drug Interactions; Hydrazones; Male; Pyridazines; Rats; Rats, Inbred Dahl; Simendan; Stroke; Valsartan; Vasodilator Agents | 2015 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan | 2015 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Stroke; Tetrazoles; Valine; Valsartan | 2010 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Losartan; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cyclic GMP-Dependent Protein Kinases; Hypertension; Nitric Oxide; Rats; Receptors, Angiotensin; Stroke; Tetrazoles; Valine; Valsartan; Vasodilation | 2006 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
The JIKEI trial.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Japan; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Valine; Valsartan | 2007 |
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Basilar Artery; Blood Pressure; Brain; Enalapril; Enzyme Inhibitors; Hypertension; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan | 2001 |